Skip to main content
. 2024 Dec 7;16(23):4108. doi: 10.3390/cancers16234108

Figure 2.

Figure 2

Validation of mocetinostat, CUDC-101, and pracinostat in suppressing HNSCC spheroid growth in combination with X-ray irradiation. Growth of FaDu spheroids in the presence of (A) mocetinostat, (B) CUDC-101, and (C) pracinostat (all 0.2 µM) alone, and following a 2 Gy or 4 Gy dose of X-rays in comparison to the DMSO-treated control. Shown is the mean fold increase in spheroid volume ± SE across three independent experiments normalised against the volume observed on day 3 post-seeding, which was set to 1.0. (D–F) Images of the spheroids with the different treatments on days 3 and 15 post-seeding. (G–I) Fold inhibition in spheroid volume ± S.E as a function of radiation dose determined between days 3 and 15 post-seeding across three independent experiments normalised to the respective unirradiated control, which was set to 1.0. * p < 0.05, ** p < 0.002 on two-sample t-tests.